Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer

Benkö, G; Spajić, Borislav; Krušlin, Božo; Tomas, Davor

doi:10.1016/j.urolonc.2011.03.007

Cited by 38 publications

(42 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is increasingly recognized as a specific cancer stem cell marker for a variety of tumors [29,30]. Reports showed a negative prognostic impact of high EpCAM expression in certain cancers [31,32]. In the normal adult liver, EpCAM is only expressed in bile duct epithelium (i.e., it is not expressed in hepatocytes).…”

Section: Epcammentioning

confidence: 99%

Recent advances in cancer stem cell research for cholangiocarcinoma

Kokuryo

Yokoyama

Nagino

2012

J Hepato Biliary Pancreat

View full text Add to dashboard Cite

Cancer stem cells have been identified as cells with the capacity to self‐renew and differentiate into multiple lineages of human malignancies. Cholangiocarcinoma is one of the most difficult intra‐abdominal malignancies that can be treated using a surgical approach. Chemotherapy in addition to surgery is necessary to improve patient survival. However, its clinical benefit is limited, and, to date, no other effective anticancer drug is available for this disease. Several reports have shown the existence of cholangiocarcinoma stem cells. Cell surface antigens such as CD133, CD24, EpCAM, CD44, and others have been used to isolate cholangiocarcinoma stem cells. In general, enhanced expression of these markers in resected specimens of cholangiocarcinoma was associated with malignant potential. Distinct and specific pathways are expected to be present in cancer stem cells compared to other cancer cells that have no stem cell properties. To date, reports showing possible signaling pathways in cholangiocarcinoma stem cells are limited. More research is anticipated. Targeting therapies for surface molecular markers or specific signaling pathways of cholangiocarcinoma stem cells may be important in order to change the clinical outcome of patients with this disease. However, no clinical trial has been performed so far. This review will focus on the markers and signaling pathways used to define cholangiocarcinoma stem cells. A novel therapeutic approach of targeting cholangiocarcinoma stem cells will also be discussed.

show abstract

Section: Epcammentioning

confidence: 99%

Recent advances in cancer stem cell research for cholangiocarcinoma

Kokuryo

Yokoyama

Nagino

2012

J Hepato Biliary Pancreat

View full text Add to dashboard Cite

show abstract

“…First, high expression of either antigen is correlated with a tendency for recurrence. This holds true for PSMA, as its expression in primary prostate cancer is positively correlated with factors, like a high Gleason grade, a higher tumor stage and, most important in this case, biochemical recurrence [11,18] [34]. However, other research groups found conflicting results [26,30,65].…”

Section: Discussionmentioning

confidence: 99%

“…The expression of EpCAM is inversely related to prognosis in several carcinomas [33]. For prostate cancer, this relation is controversial [32,34].…”

Section: Introductionmentioning

confidence: 99%

PSMA, EpCAM, VEGF, and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy.

Hoving

Ananias

Rybalov

et al. 2014

JCO

View full text Add to dashboard Cite

Abstract:In this retrospective pilot study, the expression of the prostate-specific membrane antigen (PSMA), the epithelial cell adhesion molecule (EpCAM), the vascular endothelial growth factor (VEGF) and the gastrin-releasing peptide receptor (GRPR) in locally recurrent prostate cancer after brachytherapy or external beam radiotherapy (EBRT) was investigated, and their adequacy for targeted imaging was analyzed. Prostate cancer specimens were collected of 17 patients who underwent salvage prostatectomy because of locally recurrent prostate cancer after brachytherapy or EBRT. Immunohistochemistry was performed. A pathologist scored the immunoreactivity in prostate cancer and stroma. Staining for PSMA was seen in 100% (17/17), EpCAM in 82.3% (14/17), VEGF in 82.3% (14/17) and GRPR in 100% (17/17) of prostate cancer specimens. Staining for PSMA, EpCAM and VEGF was seen in 0% (0/17) and for GRPR in 100% (17/17) of the specimens' stromal compartments. In 11.8% (2/17) of cases, the GRPR staining intensity of prostate cancer was higher than stroma, while in 88.2% (15/17), the staining was equal. Based on the absence of stromal staining, PSMA, EpCAM and VEGF show high tumor

show abstract

“…Next, Poczatek et al and Benko et al found that there was no expression of EpCAM in prostate stroma [5,7]. Based on these results, EpCAM would be an attractive specific target for imaging purposes in prostate carcinoma.…”

Section: Introductionmentioning

confidence: 98%

“…There are several studies that show a significantly elevated expression of EpCAM in prostatic carcinoma compared with benign prostate epithelium [5][6][7]. Next, Poczatek et al and Benko et al found that there was no expression of EpCAM in prostate stroma [5,7].…”

Section: Introductionmentioning

confidence: 99%

EpCAM expression in lymph node and bone metastases of prostate carcinoma: A pilot study.

Hoving

Campos

Jong

2014

JCO

View full text Add to dashboard Cite

Abstract:There is an urgent need for new imaging modalities in prostate carcinoma staging. A non-invasive modality that can assess lymph node and bone metastases simultaneously is preferred. Epithelial cell adhesion molecule (EpCAM) is a membranous protein of interest as an imaging target since it is overexpressed in prostatic carcinoma compared with benign prostate epithelium and compared with stroma. However, EpCAM expression in lymph node metastases is sparsely available in the literature and EpCAM expression in bone metastases is yet unknown. The current study evaluates the expression of EpCAM in prostate carcinoma lymph nodes, in matched normal lymph nodes, in prostate carcinoma bone metastases, and in normal bone by immunohistochemistry. EpCAM was expressed in 100% of lymph node metastases (21 out of 21), in 0% of normal lymph nodes (0 out of 21), in 95% of bone metastases (19 out of 20), and in 0% of normal bone (0 out of 14). Based on these results, EpCAM may be a feasible imaging target in prostate carcinoma lymph node and bone metastases. Prospective clinical trials are needed to confirm current results. Preoperative visualization of prostate carcinoma metastases will improve disease staging and will prevent unnecessary invasive surgery.

show abstract

Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer

Cited by 38 publications

References 23 publications

Recent advances in cancer stem cell research for cholangiocarcinoma

Recent advances in cancer stem cell research for cholangiocarcinoma

PSMA, EpCAM, VEGF, and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy.

EpCAM expression in lymph node and bone metastases of prostate carcinoma: A pilot study.

Contact Info

Product

Resources

About